Sutro Biopharma (STRO): Eigentümerstruktur
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| 47,231 US Dollar | 10 | 3 | 0 | 1 | 0 |
| #Shares | Short [%] | Short Ratio |
| 16.581.171 | 11,18 | 5,93 |
Eigentümerstruktur
Analyse der Aktionärsstruktur und institutionellen Investoren
Unternehmensdaten
Grundlegende Informationen
Grunddaten
Name Sutro Biopharma
Mitarbeiter 128
Handelsplatz NASDAQ
Ticker Symbol STRO
IPO Datum 2018-09-27
Adresse 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Webseite https://www.sutrobio.com
Unternehmensführung
| Rang | Name | Position |
|---|---|---|
| 1 | Ms. Jane Chung R.Ph. | CEO & Director |
| 2 | Mr. Gregory K. Chow BA, CPA, MBA | Chief Financial Officer |
| 3 | Dr. Hans-Peter Gerber Ph.D. | Chief Scientific Officer |
| 4 | Dr. James R. Swartz DSc, Ph.D., Sc.D. | Founder |
| 5 | Mr. Devendra Luhar | Senior Vice President of Technical Operations |
Aktionärsverteilung
Aufteilung der Investoren
Größte Investoren
| Rang | Inhaber | Anteile | Wert |
|---|---|---|---|
| 1 | Perceptive Advisors LLC | 7,87% | 12,17 Mio. USD |
| 2 | Bvf Inc | 7,55% | 11,68 Mio. USD |
| 3 | Affinity Asset Advisors, LLC | 7,07% | 10,94 Mio. USD |
| 4 | BlackRock Inc | 6,77% | 10,47 Mio. USD |
| 5 | Samsara BioCapital, LLC | 6,41% | 9,92 Mio. USD |
| 6 | Kynam Capital Management, LP | 5,26% | 8,14 Mio. USD |
| 7 | Orbimed Advisors LLC | 4,49% | 6,94 Mio. USD |
| 8 | Balyasny Asset Management LLC | 4,29% | 6,64 Mio. USD |
| 9 | Vanguard Capital Management, LLC | 4,19% | 6,48 Mio. USD |
| 10 | Eventide Asset Management, LLC | 3,53% | 5,46 Mio. USD |
| 11 | Velan Capital Investment Management LP | 3,09% | 4,78 Mio. USD |
| 12 | Woodline Partners LP | 2,76% | 4,27 Mio. USD |
| 13 | ADAR1 Capital Management LLC | 2,44% | 3,77 Mio. USD |
| 14 | Geode Capital Management, LLC | 2,35% | 3,64 Mio. USD |
| 15 | Acadian Asset Management LLC | 2,25% | 3,49 Mio. USD |
| 16 | Millennium Management LLC | 2,21% | 3,42 Mio. USD |
| 17 | State Street Corp | 1,85% | 2,86 Mio. USD |
| 18 | Merck & Co Inc | 1,64% | 2,54 Mio. USD |
| 19 | Longwood Capital Partners LLC | 1,63% | 2,52 Mio. USD |
| 20 | Ameriprise Financial Inc | 1,48% | 2,28 Mio. USD |